Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Breye Therapeutics has raised $76.7M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Breye Therapeutics's investors include BioInnovation Institute, Novo Holdings, Innovestor, Mission BioCapital, Export and Investment Fund.
Breye Therapeutics is headquartered in Hørsholm, Denmark.
Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Breye Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Breye Therapeutics — Funding & Investors." VCBacked, September 29, 2026, https://www.vcbacked.co/company/breye-therapeutics. Accessed October 17, 2026.
VCBacked. (2026). Breye Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/breye-therapeutics
{{cite web |title=Breye Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/breye-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated